Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ResMed Inc. (RMD) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ResMed’s common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol RMD, and its filings offer detailed insight into governance, compensation, capital returns, and financial performance.
Among the key documents available are Form 8-K current reports, where ResMed discloses material events. Recent 8-K filings describe quarterly and annual results of operations, dividend declarations, and changes in the composition of the board of directors. They also cover amendments to equity-based incentive plans and the employee stock purchase plan, including increases in reserved shares and changes to plan terms approved by stockholders at the annual meeting.
Investors can also review the company’s Definitive Proxy Statement on Schedule 14A, which discusses board structure, director elections, executive compensation, and long-term strategic priorities. The proxy materials outline ResMed’s mission around sleep and breathing health, its 2030 goals, and its approach to aligning incentive programs with performance and shareholder interests.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex sections, such as compensation plans, dividend announcements, and voting results from the annual meeting. Users can quickly see what the board has approved, how stockholders voted on proposals, and how ResMed’s capital management policies, including recurring cash dividends, are documented in its official records.
Because Form 8-K reports and proxy statements are updated over time, the filings page offers a chronological view of ResMed’s regulatory history, from financial disclosures to governance changes. This makes it a useful resource for investors who want to understand how the company reports its performance, manages equity plans, and communicates significant events through the SEC’s EDGAR system.
RESMED INC Chief Financial Officer Brett Sandercock reported an open-market sale of 1,000 shares of ResMed Common Stock. The shares were sold at a price of $224.31 per share.
After this transaction, he holds 83,495 shares directly. The sale was conducted under a Rule 10b5-1 plan adopted on February 19, 2025.
ResMed Inc. director Peter C. Farrell reported an open-market sale of 2,000 shares of ResMed Common Stock at $225.00 per share. After this transaction, he directly holds 60,773 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than timed discretionarily.
Rule 144 sale notice by Peter C. Farrell. The filing lists securities to be sold under Rule 144 and reports recent open-market sales. It shows option-derived or option-related common shares dated 11/11/2014 (1,890 shares) and 11/11/2015 (110 shares). The filing also reports three recent common-stock sales of 2,000 shares each on 01/07/2026, 02/04/2026, and 03/04/2026.
RMD reported proposed sales of common stock via Form 144 by an affiliate. The filing lists three separate proposed sales of 1,000 shares each with trade dates 01/02/2026, 02/02/2026, and 03/02/2026, and reported values of $241,750.00, $257,030.00, and $254,300.00 respectively. The filing also lists a prior restricted stock vesting of 1,000 shares with an 11/11/2023 grant date and identifies Fidelity Brokerage Services LLC as the broker.
ResMed Inc shares were reported as having zero beneficial ownership by The Vanguard Group in an amended Schedule 13G/A. The filing states Vanguard underwent an internal realignment on January 12, 2026 and certain subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538. The amendment is signed on 03/27/2026.
ResMed Inc. Chairman and CEO Michael J. Farrell exercised options to acquire 4,991 shares of ResMed common stock at $146.34 per share, then sold 4,991 shares at a weighted average price of $251.0322 per share. The filing notes the sale was conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024. After these transactions, he holds 466,223 shares directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.
RMD filed a Form 144 reporting a proposed sale of 4,991 common shares by Michael Farrell.
The filing states the sale is pursuant to options granted 11/21/2019 and lists the trade date as 03/09/2026 with a cash transaction method. The filing also records two prior sales by the same person: 01/07/2026 (4,991 shares, $1,240,065.36) and 02/09/2026 (4,991 shares, $1,366,436.48).
ResMed Inc. director Peter C. Farrell sold 2,000 shares of ResMed Common Stock in an open-market transaction. The sale occurred on March 4, 2026 at an average price of $260.22 per share. After this trade, he directly owned 62,773 shares. The transaction was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2025.
RMD: Peter C. Farrell reports proposed sale of 2,000 common shares issuable upon exercise of a stock option granted 11/11/2014 (exercise type: Cash). The filing also lists three completed sales of 2,000 common shares each on 12/03/2025, 01/07/2026, and 02/04/2026.
ResMed Inc.'s Chief Financial Officer Brett Sandercock sold 1,000 shares of ResMed common stock in an open‑market transaction at $254.30 per share on March 2, 2026. The sale was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on February 19, 2025, and he now holds 84,495 shares directly.